QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jones-trading-initiates-coverage-on-larimar-therapeutics-with-buy-rating-announces-price-target-of-14

Jones Trading analyst Catherine Novack initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Buy rating and announ...

 baird-initiates-coverage-on-larimar-therapeutics-with-outperform-rating-announces-price-target-of-16

Baird analyst Joel Beatty initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Outperform rating and announces Pr...

 jmp-securities-reiterates-market-outperform-on-larimar-therapeutics-maintains-25-price-target

JMP Securities analyst Jonathan Wolleben reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and maintain...

 larimar-therapeutics-selected-by-fda-to-participate-in-support-for-clinical-trials-advancing-rare-disease-therapeutics-pilot-program-for-nomlabofusp-in-friedreichs-ataxia

START is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medi...

 citigroup-maintains-buy-on-larimar-therapeutics-raises-price-target-to-14

Citigroup analyst Samantha Semenkow maintains Larimar Therapeutics (NASDAQ:LRMR) with a Buy and raises the price target from...

 larimar-therapeutics-friedreichs-ataxia-investigational-drug-differentiated-from-biogens-marketed-drug

Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data fr...

 jmp-securities-reiterates-market-outperform-on-larimar-therapeutics-maintains-25-price-target

JMP Securities analyst Jonathan Wolleben reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and maintain...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION